Shareholders that lost money on Edwards Lifesciences Corporation(EW) should contact The Gross Law Firm about pending Class Action - EW

Core Insights - The Gross Law Firm is notifying shareholders of Edwards Lifesciences Corporation regarding potential legal action due to misleading statements about the company's revenue expectations for fiscal year 2024, particularly concerning the Transcatheter Aortic Valve Replacement (TAVR) platform [1] - Following disappointing financial results and a significant reduction in revenue guidance for TAVR, Edwards' stock price plummeted approximately 31.34% in one day, from $86.95 to $59.70 per share [1] Summary by Sections Allegations - Defendants allegedly provided investors with optimistic projections about TAVR's growth and demand in under-penetrated markets, which were later contradicted by actual performance [1] - The company attributed the decline in TAVR performance to increased competition from its own new therapies, which strained hospital resources [1] Financial Impact - On July 24, 2024, Edwards reported second-quarter results that fell short of expectations and revised its revenue guidance downward for the entire fiscal year [1] - The stock price drop from $86.95 to $59.70 represents a loss of about $27.25 per share, indicating a severe market reaction to the news [1] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline set for December 13, 2024 [2] - Registered shareholders will receive updates on the case's progress through a portfolio monitoring system [2]